In a recent animal study where GS 9219’s intravenous version was examined for the treatment of canine lymphoma, GS 9219 demonstrated significant activity against spontaneous non-Hodgkin’s lymphoma in pet dog subjects and was well tolerated.
The results of the study suggested that GS 9219 could be an important new therapeutic option for animals suffering from lymphoma.
VetDC president and CEO Steven Roy said the transaction with Gilead is a major milestone in the ongoing efforts to license innovative products and intellectual properties that will advance veterinary medicine.